BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Did we start the fire? A 400,000-year-old hearth sparks new questions about human evolution- Florida has quietly become America's execution capital
- Mars orbiter sees 'butterfly' crater spread its wings on the Red Planet
- The Most Compelling Innovation Developments Somewhat recently
- Why this Tennessee special election has the 'whole world' watching
- Europe pledges over €15bn for clean energy for Africa
- Foot fossil discovery could reshape human evolutionary history
- The Electric Bicycle Americans Can Confide in 2024
- Tablets: Upgrade Your Understanding Experience
